Paramus, NJ-based nutritional supplement developer Inergetics, Inc. (OTCBB: NRTI) said that Dwight “Bill” Bentley, a cornerback from Louisiana-Lafayette, signed an endorsement contract to represent the Surgex™ product line. Bentley is currently projected to go in the third or fourth round of the NFL Draft and the 108th overall best player in the upcoming NFL Draft that starts this week.
Inergetics CEO Mark Mirken commented, “We know Bill will represent our Surgex™ brand well and be a great ambassador for Inergetics in his new NFL home. We are excited to have him join our team and wish him good luck in this week’s NFL Draft!”
In a Inergetics statement, Bentley said, “With so many supplements available, it’s so valuable to find one that actually does what it claims to do. Surgex™ has helped my endurance and recovery as those are key parts of playing in the NFL. Part of my preparation for the NFL combine and draft includes maintaining my weight during training. The Surgex™ Ready to Drink product will allow my muscle and fat percentages to be in perfect balance.”
Bentley’s career numbers for the Ragin Cajuns of Louisiana Lafayette include 232 tackles, 13 for a loss, 1.5 sacks, 7 interceptions and 20 passes broken up. Bentley returned 2 interceptions for touchdowns in 2011 which was his senior year. Bentley also earned All Sun-Belt Conference honors 2 times during his collegiate career. Bentley garnered national attention in high school at Florida’s Pahokee High where he won three state championships.
Shares of Inergetics looked like they were running a 4.3, 40-yard dash in January and February; sprinting from around 12 cents all the way up to 55.7 cents. Shares have since cooled, sliding back to hold a higher-low in the area of 18 cents currently. Bentley may help give the company some fuel in the tank again to help bolster its market cap upwards from current levels of $6.26 million.
Inergetics (NRTI) Stock Quote and News:
Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/about-2/disclaimer.